

United States Patent and Trademark Office

COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE

WASHINGTON, D.C. 2023I www.uspto.gov

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/885,914

06/22/2001

Claire Dubois

85761-28

FEB 0 6 2002

CONFIRMATION NO. 5893 FORMALITIES LETTER

OC000000007172908*

Stephen P. Georgiev **SMART & BIGGAR Suite 3400** 1000 de la Gauchetiere Street West Montreal, QC H3B 4W5 CANADA

Date Mailed: 12/07/2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE **DISCLOSURES**

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice <u>MUST</u> be returned with the reply.

Customer Service Center
Initial Patent Examination Division (703) 308-1202
PART 2 - COPY TO BE RETURNED WITH RESPONSE

TRANSMITTAL LETTER (General - Patent Pending)				Docket No. 85761-28
In Re Application Of: Claire DUBOIS				
Serial No. 09/885,914		OF MARTS	Examiner Not Assigned	Group Art Unit 1614
Title: USE OF FURIN AND FURIN-LIKE PROTEASE INHIBITORS IN THE TREATMENT OF INFLAMMATORY OR MATRIX REMODELLING DISEASES				
TO THE ASSISTANT COMMISSIONER FOR PATENTS:				
Transmitted herewith is: 1. Copy of "Notice to Comply with Requirements for Patent Applications containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures; 2. Amendment and Submission of Sequence Listing; 3. Paper Copy of sequence listing (2 pages); 4. Computer readable disk copy of sequence listing; 5. Return receipt acknowledgement postcard. in the above identified application. No additional fee is required. A check in the amount of is attached. The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 19-2550 as described below. A duplicate copy of this sheet is enclosed. Charge the amount of Credit any overpayment. Charge any additional fee required.				
Stephan P. Georgiev, Reg. No. 37,563 SMART & BIGGAR				
1000 de la Gauchetiere St Suite 3400 Montreal, Quebec H3B 4W5 CANADA	reet West		on first class mail und Assistant Commis 20231.	s document and fee is being deposited with the U.S. Postal Service as der 37 C.F.R. 1.8 and is addressed to the ssioner for Patents, Washington, D.C.
			Signature	of I erson Muning Correspondence

cc:

Typed or Printed Name of Person Mailing Correspondence